Non–Small Cell Lung Cancer Coverage from Every Angle

Solange Peters, MD, PhD, on Managing Toxicities of Checkpoint Inhibitors and Chemotherapy Regimens in NSCLC

Posted: Monday, October 7, 2019

Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses the differences, in terms of administering and monitoring toxicities, between a combination checkpoint inhibitor regimen and a combination chemotherapy regimen, and which treatment may be more tolerable for patients with non–small cell lung cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.